ArticleFrontiers in microbiology2011
Genetic and Functional Diversity of Pseudomonas aeruginosa Lipopolysaccharide.
Article in Frontiers in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 289 citations in OpenAlex.
- XAB06, a glyco-humanized broad-spectrum anti-Antimicrobial agents and chemotherapy · 2026Article
- Transcriptome-Integrated Metabolic Modeling Identifies Candidate Metabolic Adjuvants in Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Human ex vivo comparison of Escherichia coli and Pseudomonas aeruginosa lipopolysaccharide-induced immune responses and cefiderocol effects in whole blood.Medical microbiology and immunology · 2026Article
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Synergistic Bactericidal Effects of R- and F-Type Pyocin Cocktails Against ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Role of cell-associated and secretion-independent virulence factors of Pseudomonas aeruginosa in microbial keratitis and anti-virulence therapeutic strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?The Journal of infectious diseases · 2026Article
- From genome to lifestyle: adaptive strategies ofApplied and environmental microbiology · 2026Article
- Genetic diversification ofApplied and environmental microbiology · 2026Article
- Genomic and biological characterization of lytic phages infecting Pseudomonas syringae associated with almond bacterial blast.Scientific reports · 2026Article
- Biophysical Modeling of Lipopolysaccharides in Gram-Negative Bacteria: From Atomic to Colloidal Models.International journal of molecular sciences · 2026Review
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- Recombinant Human IgG1 Enhances Complement-Mediated Bacteriolysis and Macrophage Phagocytosis ofACS infectious diseases · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- In vitro biofilm formation by a beneficial bacterium partially predicts in planta protection against rhizosphere pathogens.The ISME journal · 2026Article
- LPS-induced structural reorganization and polymerization drive noncanonical inflammasome activation.Science advances · 2026Article
- Understanding phage Receptor-binding protein interaction with host surface receptor: the key for phage-Mediated detection and elimination of Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Decoding a Gut Commensal Signal: Structural and Immunological Profiling of Segatella Copri Lipopolysaccharide.Angewandte Chemie (International ed. in English) · 2025Article
- Dual-action thioarylamide-based small molecules to target drug-resistant bacteria and chronic inflammation.iScience · 2025Article
- Genomic correlates of tailocin sensitivity in Pseudomonas syringae.G3 (Bethesda, Md.) · 2025Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipopolysccharide (LPS) is an integral component of the Pseudomonas aeruginosa cell envelope, occupying the outer leaflet of the outer membrane in this Gram-negative opportunistic pathogen. It is important for bacterium-host interactions and has been shown to be a major virulence factor for this organism. Structurally, P. aeruginosa LPS is composed of three domains, namely, lipid A, core oligosaccharide, and the distal O antigen (O-Ag). Most P. aeruginosa strains produce two distinct forms of O-Ag, one a homopolymer of D-rhamnose that is a common polysaccharide antigen (CPA, formerly termed A band), and the other a heteropolymer of three to five distinct (and often unique dideoxy) sugars in its repeat units, known as O-specific antigen (OSA, formerly termed B band). Compositional differences in the O units among the OSA from different strains form the basis of the International Antigenic Typing Scheme for classification via serotyping of different strains of P. aeruginosa. The focus of this review is to provide state-of-the-art knowledge on the genetic and resultant functional diversity of LPS produced by P. aeruginosa. The underlying factors contributing to this diversity will be thoroughly discussed and presented in the context of its contributions to host-pathogen interactions and the control/prevention of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.